Novocure Reports Results from P-III Pivotal Study of Tumor Treating Fields in Non-Small Cell Lung Cancer
Shots:
- The results met its 1EP and showed a significant improvement in OS for the P-III study, evaluating Tumor Treating Fields + ICI/docetaxel (experimental arm) vs ICI/docetaxel alone (control arm) for stage 4 NSCLC following progression while on or after treatment with platinum-based therapy
- Superior OS of patients treated with TTFields + ICI vs ICI alone & TTFields + docetaxel vs docetaxel alone are being evaluated as the 2EPs
- Additionally, the company plans to present complete results in an upcoming medical conference and in H2’23 plans to file PMA and CE mark to the US FDA and the EU, respectively
Ref: Novocure | Image: Novocure
Related News:- MSD Collaborates with Novocure to Evaluate Tumor Treating Fields Together with Keytruda (pembrolizumab) in Non-Small Cell Lung Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
